Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Tian, Daiyin, Battles, Michael B., Moin, Syed M., Chen, Man, Modjarrad, Kayvon, Kumar, Azad, Kanekiyo, Masaru, Graepel, Kevin W., Taher, Noor M., Hotard, Anne L., Moore, Martin L., Zhao, Min, Zheng, Zi-Zheng, Xia, Ning-Shao, McLellan, Jason S., Graham, Barney S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5707411/
https://ncbi.nlm.nih.gov/pubmed/29187732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-01858-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados